Sona Nanotech, Inc. · CSE:SONA
Sona Nanotech — Investor Presentation (November 2020)
22 slides from Sona Nanotech's investor presentation, November 2020
Slide 1: Applying Gold Nanorod Technology to Disrupt Global Rapid Diagnostics Markets
APPLYING GOLD NANOROD TECHNOLOGY TO DISRUPT GLOBAL RAPID DIAGNOSTICS MARKETS WWW.SONANANO.COM CSE:SONA | OTC:SNANF November 2020 1
Slide 2: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS This presentation contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future is forward-looking information. Forward-looking statements are based on the estimates and
Slide 3: Sona at a Glance
SONA AT A GLANCE Sona Nanotech is a nanotechnology life sciences company that has developed multiple proprietary methods for the manufacture of gold nanorods (GNR’s) Nanotechnology: the use of matter on an atomic, molecular, and supramolecular scale Gold Nanorods: gold nanoparticles that are elongat
Slide 4: Company Highlights
COMPANY HIGHLIGHTS Patent pending GNR platform technology without CTAB positions Sona to potentially disrupt the $26B1 global point-of-care diagnostic market Lead product is a 15-minute, antigen lateral flow test that screens for COVID-19 that is easy to use with proven in-field Sensitivity of 85% (
Slide 5: Sona's GNR Technology in LFA's
SONA’S GNR TECHNOLOGY IN LFA’S Lateral Flow Assays (LFA’s) are simple, fast, and low-cost Point of Care (PoC) diagnostic or screening tools which can provide rapid results (i.e. at-home pregnancy tests). Sona applies its proprietary GNR technology without CTAB in LFA’s to with a view to increasing s
Slide 6: Leveraging Real-Time Data
LEVERAGING REAL-TIME DATA Sona partners with Bond Digital Health Solutions to enable real-time data management Bond Digital Health is a leading provider of digital solutions for LFAs. Built in partnership with Bond, the Sona Connect app offers an end-to-end digital platform that enhances lateral flo
Slide 7: The Global Rapid Diagnostic Market
THE GLOBAL RAPID DIAGNOSTIC MARKET Rapid Diagnostic Tests (RDT’s) are medical screening or diagnostic tests that are mobile, quick and easy to perform, and provide rapid results. 2027 $55.35B The global PoC diagnostics market is expected to grow to $55.35 Billion USD with 9.6% CAGR over the next six
Slide 8: First Commercialization: COVID-19 Test
FIRST COMMERCIALIZATION: COVID-19 TEST Sona quickly recognized the opportunity to commercialize its GNR technology within an LFA test device to develop a rapid COVID-19 antigen test EARLY DETECTION Sensitivity of 96% and specificity of 96% in the lab and 94% and 94% in-field trials for patients with
Slide 9: History & Status of Sona's COVID-19 Rapid Antigen Test
HISTORY & STATUS OF SONA’S COVID-19 RAPID ANTIGEN TEST Q1 2020 Q2 2020 Q3 2020 Q4 2020 Achieved active In-field trials yield test COVID-19 project conjugate; positive test sensitivity of 85% and commences to COVID-19 viral antigens specificity of 90% PROOF OF MANUFACTURING FEASIBILITY DEVELOPMENT OP
Slide 10: Strong Clinical Trial and Lab Results
Strong Clinical Trial and Lab Results In-house Prototype 3rd Party Lab Prototype 3rd Party Validation Validation (MRI Global) Clinical Study (SaudiVax) • Validation that • Confirm in-house • An in-field study of 99 people was Goals biological test performance conducted in a high prevalence component
Slide 11: COVID-19 Market Opportunity
COVID-19 MARKET OPPORTUNITY With only a handful of rapid tests approved, demand still far outweighs production capacity DAILY COVID-19 TESTS PER THOUSAND PEOPLE GLOBAL DEATHS FROM COVID-19 PROJECTED TO DOUBLE IN FOUR MONTHS (Rolling 7-day average) Sona believes that the demand for rapid testing solu
Slide 12: The Importance of Frequent Rapid Antigen Test Screening
THE IMPORTANCE OF FREQUENT RAPID ANTIGEN TEST SCREENING Turnaround time and frequency can be more important than sensitivity in stopping the spread of COVID-19 “ Antigen tests are distinct. They only detect…when the virus is in the process of being infectious. These tests are actually extremely good
Slide 13: Private Sector Use Cases
PRIVATE SECTOR USE CASES FOCUS TO BE ON INDUSTRIES THAT REQUIRE PHYSICAL PRESENCE TO CREATE VALUE HIGH MINING AIRPORTS ADDITIONAL CHANNELS AIRLINES MEAT PACKING TO MARKET: RESTAURANTS LONG TERM • Occupational health THEME MANUFACTURING CARE CRUISE consultants PARKS SHIPS ECONOMIC BENEFIT OF HOTELS •
Slide 14: A Saliva-Based Test: Version 2.0 of Sona's Rapid COVID-19 Antigen Test
A SALIVA-BASED TEST: VERSION 2.0 OF SONA’S RAPID COVID-19 ANTIGEN TEST Sona has developed a prototype for a second generation of its rapid COVID-19 antigen test that uses saliva instead of nasal pharyngeal samples Benefits: • Less invasive sample collection means faster sample collection and greater
Slide 15: Potential Near-Term Drivers
POTENTIAL NEAR-TERM DRIVERS Sona’s rapid COVID-19 antigen test is in the regulatory review phase for approvals to manufacture and distribute SONA’s in-field and third-party lab testing results, and ongoing data collection, to support ongoing regulatory submissions and future applications. Strong dem
Slide 16: Opportunity to Disrupt Diagnostics
OPPORTUNITY TO DISRUPT DIAGNOSTICS Sona’s high sensitivity gold nanorod technology has multiple diagnostic ‘in-vitro’ applications well beyond COVID-19, all with >1B TESTS PRODUCED opportunity to gain market share from multi-billion-dollar verticals IN 2017 3 Bacterial and fungal tests to Infectious
Slide 17: Second Commercialization: Concussion Screening Test
SECOND COMMERCIALIZATION: CONCUSSION SCREENING TEST Sona is applying its GNR technology to develop a rapid concussion screening test. The test is intended to detect the presence of GFAP (Glial Fibrillary Acidic Protein), a biological marker associated with concussions, typically released into the bl
Slide 18: Longer Term Applications
LONGER TERM APPLICATIONS Because they are non-toxic, Sona's gold nanorods can be used in ‘in-vivo’ applications in which they are used for tracking and targeting with the potential for profound implications. IN-VITRO IN-VIVO Diagnostics / Detection Drug Delivery Photothermal Therapy Cell Imaging Use
Slide 19: Stock Information
STOCK INFORMATION CSE:SONA | OTC:SNANF approvals. MARKET CAPITALIZATION Shares Outstanding 61M Insider Ownership 13.4% Market Cap $72M CDN 52 Week High $16.05 Previous Quarter 635,858 Average Daily Volume * As of November 27, 2020 RESEARCH COVERAGE Maxim Group | Jason McCarthy, Ph.D. SONANANO. CSE:S
Slide 20: Management & Scientific Advisors
MANAGEMENT & SCIENTIFIC ADVISORS § Responsible for new product development DR. KULBIR SINGH § Named author on 35 research papers and 2 patents Founder & Head of R&D § Ph.D. in chemistry and expert in metal nanoparticle fabrication and surface chemistry § 15 years public company experience leading st
Slide 21: Board of Directors
BOARD OF DIRECTORS DR. MICHAEL GROSS, MBBS, § Professor of Orthopaedic surgery, medical director of the Regional Tissue Bank FRCSC, ICD.D § Director of Linear Gold (sold to Brigus Gold) Director § Current director of Fortune Bay, Chair Boomersplus § Former President of Sanofi Pasteur Limited, the Ca
Slide 22: Contact
CONTACT WWW.SONANANO.COM | +1-902-209-2232 1969 Upper Water Street Suite 2001, Purdy’s Tower II Halifax, Nova Scotia, Canada B3J 3R7 DAVID REGAN KIN COMMUNICATIONS CEO Investor Relations +1-902-448-1416 +1 604-684-6730 david@sonanano.com SONA@kincommunications.com SONANANO. CSE:SONA | OTC:SNANF 21 C
Sona Nanotech — Investor Presentation (November 2020) on 6ix